ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamura, Ryosuke, Kato, Shumei, Lee, Suzanna, Jimenez, Rebecca E, Sicklick, Jason K, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057434/
https://www.ncbi.nlm.nih.gov/pubmed/32111729
http://dx.doi.org/10.1136/jitc-2019-000438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057434/
https://www.ncbi.nlm.nih.gov/pubmed/32111729
http://dx.doi.org/10.1136/jitc-2019-000438

Ejemplares similares